Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
US students studying housing, health outcomes and sustainability win 2026 Rhodes scholarships - 2Vote In favor of Your Favored Web-based Visual depiction Administration
- 3Oil Tanker Carrying Iraqi Cargo Seen Transiting Strait of Hormuz
- 4Moon rush: These private spacecraft will attempt lunar landings in 2026
- 5More parents refusing vitamin K shots for newborns, study finds
- Oldest sequenced RNA reveals details about a mammoth’s final moments 40,000 years
- Living in the dark: Gaza’s struggle for electricity
- Who was Haytham Ali Tabatabai, Hezbollah's military leader killed by Israel?
- Activist vessel collides with krill trawler in Antarctic confrontation
- Reporter's notebook: Inside the IDF’s ‘Hamas Village,’ and how Israel is rewriting urban warfare
- Viruses aren’t all bad: In the ocean, some help fuel the food web – a new study shows how
- Advocacy groups react after Mattel introduces 1st Barbie doll with autism
- South America's Memorable Destinations: A Movement Guide
- 10 Natural products to Remember for Your Eating routine for a Better You
